ROCKVILLE, Md., Feb. 2 /PRNewswire/ -- Accelovance announced today that it has completed the asset purchase of nTouch Research, a Raleigh, N.C.-based site management organization (SMO). Financial details were not disclosed. nTouch's clinical capabilities are a key component in Accelovance's strategy to provide trial management services that result in meeting trial timelines in a high quality and cost-effective manner. By combining high-level targeted patient recruitment with quality-focused, integrated, and centralized managed sites, Accelovance improves productivity and quality when conducting multi- center Phase II through IV studies. Building on its operations in China, the Company plans to add clinical sites there to further enhance global clinical trial enrollment and economics. "A strategic blend of upper management expertise, outstanding investigators, and the knowledge of on-site employees will allow Accelovance to better serve our clients. Our vision is to revitalize the way SMOs and trial sponsors work together," said Accelovance President and CEO, Stephen J. Trevisan. Accelovance is a privately held company headquartered in Rockville, Maryland. With over a dozen highly-rated research centers throughout the United States, Accelovance provides Phase II-IV clinical trial services that include investigator selection, patient recruitment and study management services for pharmaceutical, CRO, and biotechnology industries. Accelovance has a commitment to sponsors, investigators and study subjects to conduct each study with dedication and high standards under good clinical practice (GCP) guidelines. Its secondary mission is to form strong partnerships to take advantage of the rapidly growing medical market in China. This will be accomplished by structuring relationships between partners with quality products and services to address unmet medical needs in China. For more information, visit the company's website at http://www.accelovance.com. CONTACT: Stephen J. Trevisan, +1-301-222-2218, or Garrett D. Smith, +1-301-222-2212, both of Accelovance.